News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
SBP GROUP's TQB6411 Clinical Study Shows Favorable Safety Profile at Effective Dose
SBP GROUP (01177.HK) announced that the data from a Phase I first-in-human study of TQB6411 “EGFR/c-Met ADC”, an investigational national Category 1 innovative drug ind...
Reset
Send
The window will close in 5 seconds
SBP GROUP's TQB6411 Clinical Study Shows Favorable Safety Profile at Effective Dose
Close
Recommend
14
Positive
19
Negative
2
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

SBP GROUP (01177.HK)  -0.150 (-3.145%)    Short selling $107.69M; Ratio 28.596%   announced that the data from a Phase I first-in-human study of TQB6411 “EGFR/c-Met ADC”, an investigational national Category 1 innovative drug independently developed by the Group’s subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), in patients with advanced solid tumours, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

The study demonstrated that TQB6411 has a favorable safety profile at effective doses, particularly in terms of its low haematological toxicity. TQB6411 exhibits a stronger binding affinity for c-Met than for EGFR, with a potency ratio of 1:2. Such characteristic enhances the killing effect of TQB6411 on tumour cells with high c-Met expression, while mitigating EGFR-mediated adverse events, such as skin toxicity.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-03 16:25.)

Related News M Stanley Cuts SBP GROUP (01177.HK) TP to HKD7.8, Rating Overweight

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.